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The Clinical
Spectrum of HIV

Implications for
Public Policy

Infections:

Kenneth H. Mayer, M.D.

The term acquired immunodeficiency syndrome (AIDS)

is

a definition developed by the

Centers for Disease Control to explain the epidemic of immunosuppression first seen in

among gay and bisexual men and intravenous drug users in the early
now known that the human immunodeficiency virus (HIV) is the necessary
agent for the compromise of the immune system which results in AIDS; however, there is a
wide range of manifestations associated with HIV infection. Individuals with AIDS tend to
the United States

1980s.

It is

have severe opportunistic infections or malignancies, and the vast majority of individuals
die within two years after the diagnosis. At least a fourth of the individuals with

HIV infec-

one study were found to remain asymptomatic after seven years of infection. Between the long period of asymptomatic infection and the development of life-threatening
tion in

opportunistic infections, individuals
tion.

Some

individuals

may develop

may develop subacute manifestations of HIV infec-

constitutional symptoms, without any other medical

explanation. The clinical use of tests of immunologic function as well as newer tests that

may describe the type of HIV infection, such as the serum antigen
ability

test,

may enhance the

more specific information as to their prognoutilization of newer diagnostic tests may allow

of clinicians to give infected patients

As newer therapies are developed, the
more rational treatment plans. The data suggesting increasing efficacy of
Azidothymidine (AZT), as well as the development of newer chemotherapeutic agents, may
lead to more widespread HIV testing in order to detect infection at early stages and intervene with specific therapies. Use of the test as a means of altering behavior remains controversial. The development of newer therapies is hindered by the need to avoid exposing
HIV-infected individuals to agents that subsequently turn out to be harmful, such as HPA23 and Suramin. But this must be balanced with the urgent need of individuals to try promsis.

for staging

who are treated with
may be a move in the

ising therapeutic agents. Preliminary data suggest that individuals

AZT at earlier stages of HIV infection may do better; thus,

there

future to treat people with AZT. The clinical dilemma will persist for

and the

cost of care for individuals with

Although the

Dr. Kenneth H.

illness is frequently fatal,

AIDS and HIV infection

it is

most appropriate

to

will

some time

to

come,

be extremely high.

be considerate of

Mayer is assistant professor of medicine at Brown University and at Memorial Hospital in
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Pawtucket, Rhode Island, and
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the individual

's

more aggressive therapies, given the variability of HIV
and the fact that new therapeutic breakthroughs are being made

desire to have

infection for each person

every day.

profoundly
The AIDS epidemic
ranging from
is

affecting the general public regarding issues of

the sexual counter-revolution to

social policy,

how one deals with

primeval fears of contagion in the age of instant global transport. Medical clinicians comprise one of the groups that have had to respond

with this epidemic. They were also

among

most

to the multiple

those individuals

something new was occurring with the disease

is

now perceived

York

City,

as a global problem, the

new epidemic was a clinically complicated

associated with deranged immunoregulation.
literature regarding

what

is

now known

men with multiple

sexual part-

— that New
— were perceived to be developing illnesses

few intravenous drug users,

San Francisco, and Los Angeles

recognized that

Nosology is that branch
of diseases, and at the outset of

nosological question. Young males, predominantly gay
ners, as well as a

conundra associated

initially

in the early 1980s.

of medical science which deals with the classification

what

who

in a discrete

The

first

AIDS

as the

number of cities

is,

published report in the medical

epidemic was in the Morbidity and

Mortality Weekly Report a newsletter of the Centers for Disease Control (CDC), which
,

described several cases of Pneumocystis carinii pneumonia in Los Angeles.

noted that

whether

all

1

The authors

of the infected individuals were exposed to cytomegalovirus and wondered

this virus

could be playing a role that could explain

why homosexually active
who were iatro-

males were developing a disease previously associated with individuals
genically

immunocompromised or malnourished. The subsequent reports of Kaposi's
may occur in immunocompromised individuals, and the appearance of

sarcoma, 2 which

Pneumocystis carinii in individuals

who presumably

could have been infected via contam-

inated needles, helped to buttress the possibility that a specific infectious agent that could

be transmitted sexually and via blood was resulting in the epidemic of immunosuppression.

However, for several years an ongoing debate raged, with

felt that this

at least three sides.

epidemic was due to a new infectious agent; some thought

it

was due

Some

to agents

already present which might have undergone evolution (such as cytomegalovirus, or a

combination of infectious agents); and others
of the

immune

felt that

the epidemic represented a burnout

system, because high-risk individuals tended to be exposed to multiple

agents, drugs, and other nonspecific antigens that tended to
fenses. Subsequent elucidation of the retroviral etiology of

abetted by careful epidemiological studies linking
a very tight case that

HIV was the etiologic agent,

5

new

overwhelm

their host de-

HIV infection,

risk groups

3

4

which was

and helping

to develop

has not necessarily diminished the

More than six years into the
who are infected with HIV

diagnostic and therapeutic questions facing clinicians today.

epidemic, clinicians

still

cannot accurately

tell

individuals

when and whether they will develop AIDS and whether they should take Azidothymidine
(AZT) or one of the other, less studied treatment regimens.

Definition of the Clinical Spectrum of the Epidemic

When the epidemic of immunodeficiency was first recognized in the early

1980s, the

Centers for Disease Control was given the responsibility of trying to define a process

whose

origin was unclear,

whose

etiology was

38

unknown, and whose natural history was

uncharted. Fortunately, the revolution in immunologic understanding and diagnostic

techniques which had occurred in the late 1970s allowed for the conceptualization that a

major

cell that regulated

many

aspects of host

immune response,

the T-helper lymphocyte,

was numerically depleted and functionally impaired. All the individuals with this type of
impairment manifested one or another of an increasing number of atypical infections and
neoplasms. 6 The aggregation of a specific type of immunologic impairment, specific
distinctive

and atypical types of illnesses,

in individuals with specific risk behaviors,

allowed the Centers for Disease Control to evolve a case definition of what came to be

known

as the acquired immunodeficiency syndrome.

faced was

how

to define this process that

was

still

The dilemma that these investigators

so unclear without lumping into

it

indi-

were due to other causes while at the
same time not leaving out the increasing numbers of individuals with some evidence of Thelper lymphocyte immunologic impairment. At an early point in time, the CDC decided
to take a narrow-based approach in which cases reported which related to the epidemic
would be those of the sickest individuals who did not have other reasons for immunosupression but who had one of a specific laundry list of clinical syndromes that were distinc7
tively atypical in individuals whose immune systems were intact. This approach was
extremely effective in picking up individuals who had the classic signs of immunologic
impairment and conditions which were the most commonly seen in the course of the epidemic, such as Pneumocystis carinii pneumonia and Kaposi's sarcoma. Neither of these
conditions occurred with any significant frequency in individuals who were not immunoviduals

whose

infections or neoplasms, or both,

suppressed or elderly, or both.

However, other individuals developed illnesses that were not specific to immunocom-

promised individuals, but the severity of their manifestations suggested

that they

were

immunologically impaired. For example, herpes simplex infection around the mouth or

Table 1

Summary of Centers for Disease Control (CDC)
Classification

System for HIV Infections

Group

I.

Acute infection

Group

II.

Asymptomatic

Group

III.

Persistent generalized

Group

IV.

Other disease

Subgroup A.

infection*

lymphadenopathy

Constitutional disease

Subgroup

6.

Neurological disease

Subgroup

C.

Secondary infectious diseases

Category C-1

.

Specified secondary infectious diseases
listed in the CDC surveillance definition for AIDS*

Category C-2. Other specified secondary infectious diseases

Subgroup

D.

Secondary cancers*

Subgroup

E.

Other conditions

*Patients

in

groups

II

and

III

may be subclassified on the

includes those patients whose clinical presentation
used by the CDC for national reporting.
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basis of a laboratory evaluation.

fulfills

the definition of

AIDS
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the perirectal area

is

uncommon

not an

infection of homosexually active males

who have

multiple partners, but the persistence of perianal ulcerations around the rectum in the
setting of immunologic abnormalities seen in

blood

tests

was highly suggestive of the

wider spectrum of the epidemic. Even more difficult for the clinician were individuals

who had persistent wasting syndromes accompanied by significant weight losses, persisand malaise, who despite extensive medical evaluations did not have specific
infectious agents always identified as the source of their problems. Other individuals who
are at high risk to develop AIDS continue to be well for long periods of time with asymptomatic immunologic abnormalities, or may show evidence only of persistent generalized
tent fevers,

lymph gland swelling associated with blood test abnormalities. 9 Astute clinicians in the
cities where the epidemic was first appreciated noted that individuals often progressed
from asymptomatic conditions to those of lesser severity to the more severe opportunistic
infections. Others noted that certain processes were more common in individuals with
specific risk characteristics; for example, homosexually active males were more likely to
have Kaposi's sarcoma than individuals who were intravenous drug users.
Even before HIV was delineated as the etiologic agent, clinicians and epidemiologists
8

10

expanded

their vision of the

conditions defined as

epidemic to incorporate the concept of the iceberg, with those

AIDS representing the tip of the iceberg.

Progression from asymp-

tomatic high-risk status to full-blown opportunistic infections helped to develop this con-

Even more convincing was the delineation of the similar spectrum of degrees of
immunocompromise among individuals who had received blood transfusions from individuals who had subsequently developed AIDS, and among individuals from other nations
who did not have any history of homosexual activity or intravenous drug use. The development of an intellectual model of a process that resulted in immunocompromise, with
cept.

opportunistic infections and neoplasms subsequently supervening, was validated once

HIV was isolated, and appropriate

seroepidemiologic studies were undertaken which

confirmed the increased prevalence of this virus

in individuals with

AIDS and related

symptom complexes.
One might ask, Why should the arbitrary definition of AIDS continue to be reported
when one can actually monitor the prevalence of the causative agent itself? Although
infection with HIV is necessary for an individual to develop AIDS, it is still not clear
whether

all

individuals

that took place in

diseases which

is

who

are HIV-infected will ultimately develop the full-blown syn-

on this issue are derived from a hepatitis B vaccine study
San Francisco from 1978 to 1980 at a clinic for sexually transmitted
run by the city health department. Of the gay and bisexual men who

drome. The best data

that bear

were found to be infected with HIV between 1978 and 1980, more than one-third developed CDC-defined AIDS by 1987, and approximately 25 percent remain completely
asymptomatic. The range for individuals in the middle zone includes asymptomatic
immunologic abnormalities; persistent generalized lymphadenopathy; minor opportu11

nistic infections

symptoms.

such as thrush and zoster; and the presence of persistent constitutional

We must be careful about generalizing from this cohort,

nition of the

AIDS epidemic in the early

what constituted safer sexual

since prior to recog-

1980s, there was no widespread education as to

practices. If repeated exposures to

HIV or other sexually

transmitted viruses such as cytomegalovirus and Epstein-Barr virus result in synergistic
initial HIV infection, then the rates of progression from
HIV infection from the men in this cohort could represent a worst-case

immunosuppression with the
asymptomatic

scenario. However,

no single study of homosexual or heterosexual exposure has indicated
HIV infection results in more rapid immunocompromise, and

that unsafe sex after initial

40

thus the data generated from this cohort can be utilized as a point of reference despite

such sexual practices.

The finding

number of individuals who are HIV-infected develop

that a substantial

blown AIDS does not mean
present time. Individuals

that a separation in reporting of

who do

not have

AIDS

is

full-

not useful at the

AIDS may need to utilize many health care

services, including multiple laboratory tests, medical evaluations of recurrent

minor

opportunistic infections, and counseling and support services. Individuals with

AIDS

much more severe medical illnesses; thus, monitoring the increasing number
of individuals who frequently require intensive, tertiary services is a useful way to monitend to have

and

tor health care utilization

to assist planners in projecting

what types of resources

will be necessary to deploy as the epidemic continues to progress.
that has

been shown

to assist in extending life in individuals with

defined AIDS-related complex (ARC), a term

it

AZT is the first drug

AIDS

or with the

that usually relates to constitutional

ill-

symp-

ultimately forestall the progression to

known at the present time whether AZT will
AIDS of many individuals whose HIV infection is

rapidly progressing. ("Ill-defined"

used here as a descriptor because specialists do not

toms associated with

HIV

infection.

It is

is

not

agree on the definition of AIDS, and therefore various articles and other writings refer to
different levels of morbidity.) If current projections by the Centers for Disease Control

are correct, between

1

million and 1.5 million Americans are currently infected with

HIV, and by 1991 more than a quarter million of them will have developed CDC-defined
infections or neoplasms that are

The Wide Spectrum

now

described as one of the conditions defined as AIDS. 12

of HIV Infection

Intimate sexual contact with an HIV-infected partner or the sharing of contaminated needles does not invariably result in
active

male partners conducted

cordant (that

is,

HIV infection.

in Boston,

In a prospective study of homosexually

more than

one partner was seronegative and the

one-third of the partners were disother, seropositive) despite possible

high-risk anal exposures to infected ejaculate on the part of the susceptible seronegative
partner.

,3

Whether

certain individuals are intrinsically

HIV or whether some infected individuals

more

able to resist infection with

are less capable of transmission

is

not clear at

Some lines of data suggest that individuals may become more efficient
in the transmission of HIV infection the longer they carry the virus. This observation has
been made concerning hemophiliacs and their spouses; concerning homosexually active
the present time.

14

male partners;

Once an

in the recipients of infected blood;

individual has

become

15

and

infected with HTV,

it

in perinatal studies.

16

most often takes between three and

twelve weeks to develop detectable antibodies. The vast majority of individuals have de-

HIV infection by six months, although there are rare individuals who
HIV antibodies after several years of follow-up. Newer diagnostic
such as the detection of serum antigen, may permit demonstration that an HTV expo-

tectable

markers for

have not developed
tests,

sure has occurred prior to the development of antibody. At the time of seroconversion,
individuals

may

drome; rashes

manifest a number of symptoms, including a mononucleosis-type syn-

that

plained fevers. 17

18

may be hivelike or maculopapular; an

aseptic meningitis;

and unex-

However, many individuals, perhaps most, may remain completely

asymptomatic for several years after becoming HIV-infected. In response
ing understanding of the wide spectrum of
classification system (see table 1)

HIV

infection, the

to the increas-

CDC has developed a

which describes individuals with acute

infection,

asymptomatic infection, and persistent generalized lymphadenopathy, as well as those
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HIV

who have clinically

significant

tions, neurological

syndromes, or constitutional symptoms, or a combination of these. 19

The

infection, that

individuals in the first three groups of the

variable courses. For example,

is,

opportunistic neoplasms and infec-

CDC classification system have highly

some persons may have persistent HIV-related lymph-

adenopathy for many years without any other subsequent untoward sequelae. 20 However,

once individuals develop systemic complaints and constitutional symptoms, there may be
a rapid progression to

more

severe complications of HIV infection which are subsumed

AIDS (see tables 2 and 3).
who have early HIV infection present difficult decisions

under the acronym
Individuals

for clinicians

regarding questions of appropriate interventions to prevent them from further

compromise. Several studies are now under way

(ATEUs)

that are

funded by the National

in the

Institutes of

immuno-

AIDS Treatment Evaluation Units

Health (NIH). These studies will

attempt to determine whether asymptomatic seropositive individuals will benefit from

AZT. However, it may take several years to answer this question. In the meanmany worried individuals who are aware that a subsequent clinical decline is a fre-

receiving
time,

quent outcome of long-standing asymptomatic infection try to obtain drugs through black

markets

— drugs that may be homemade, such as AL-721

from Mexico, such
about

how

as Ribavirin.

,

or that

may be smuggled in

Another dilemma for clinicians concerns the decision

aggressively to diagnostically evaluate individuals with generalized lymph-

many clinicians were more likely to do
lymph node biopsies on patients who had persistent swollen glands, even in the absence of
constitutional signs. It has subsequently emerged that without the evidence of hematologic
or clinical abnormalities, biopsy most often results in finding a lymph node whose histoadenopathy. At the early phase of the epidemic,

logic pattern

is

termed "reactive

follicular hyperplasia," a pattern that tells the health care

workers only that the lymph gland
nostic information.

is

"turned on," without conveying any specific prog-

21

Whether or not an individual has swollen lymph glands, the onset of so-called constituthat is, persistent fevers, chills, sweats, weight loss, and malaise
is
symptoms

—

tional

generally a negative prognostic sign.

—

22

HIV infection may
some of which may or may not portend the

Obviously, individuals with

have any of these symptoms for other reasons,

onset of an opportunistic infection. Very often, HIV-positive individuals and their clinicians are in a state of worried anticipation once these types of symptoms supervene.

An

episode of influenza can be emotionally upsetting and result in unnecessary diagnostic
studies in anxious seropositive persons. The chronicity of symptoms, generally lasting
more than a month, may be a sign that the HIV infection has resulted in a new state of
more severe immunocompromise and susceptiblity to opportunistic infection. Individuals
with constitutional symptoms generally need to have an extensive medical workup, since
some of the conditions they have may be treatable and may be more amenable to therapy
early. However, HIV infection itself can result in any of these symptoms,
wide range of neurological findings, though some individuals may undergo
expensive workups without obtaining a definitive answer. However, one cannot take the
attitude that if the workup initially is negative, there is no use in repeating it if further
if

diagnosed

as well as a

symptoms develop. Unfortunately, once an
ity

of the

immune system to respond to

individual undergoes a diminution in the abil-

specific infectious processes, then there

pensity for developing multiple infections, and thus each

new

sign or

is

a pro-

symptom has

to

be

symptom complexes. This possibility for serial infections, sometimes with multiple agents, tends to make the medical management of individuals with HIV infection particularly labor-intensive and costly. The clinician must always
evaluated independently of prior

42

.

balance the aggressiveness of the clinical workup against appropriate therapeutic options

AIDS-related complex, but more often than not,

for individuals with the

proceed with the

tion of specific clinical conditions can lead to appropriate therapy

improved quality of life

The

opportunistic infections that individuals develop with
in a specific

much more common

is

desirable to

and may result

in

an

for the patient.

nisms that are ubiquitous

monia

it is

of specific organisms or the defini-

latest diagnostic tests, since isolation

in

AIDS may be due to orga-

environment, so that Pneumocystis carinii pneu-

North America and Europe than

whereas

in Africa,

opportunistic infections

much more common there. Other
represent reactivation of chronic latent viruses that may have

been acquired

ages as the result of intimate contact, such as herpes simplex,

cryptococcal meningitis and Isospora belli enteritis are

at earlier

cytomegalovirus, and Epstein-Barr virus. However, in individuals with

immunodeficiency due

to

HIV, these viruses may reactivate

forms, so that chronic, persistent perianal ulcerations

cytomegalovirus

may

AIDS and

may be due to herpes

result in colitis, blindness, or a refractory

is

that with appropriate

simplex, 23 or

pneumonia, syndromes

associated with this virus which are seen only in severely debilitated hosts.

drum in individuals with AIDS

24

One conun-

medical technology, most of these

Table 2

Opportunistic Infections Indicative of a Defect in
Cellular Immune Function Associated with AIDS

A. Helminthic Infection
1

B.

.

beyond the

Strongyloidiasis (disseminated

gastrointestinal tract)*

Protozoan Infection
1

2.

Pneumocystis carinii pneumonia
Disseminated toxoplasmosis, or toxoplasma encephalitis, excluding congenital infection

3.

Chronic Cryptosporidium enteritis (>

4.

Chronic Isospora

belli enteritis

(

>

1

1

month)

month)

C. Fungal Infection

D.

1

Candida esophagitis, bronchopulmonary candidiasis*

2.

Cryptococcal meningitis, or disseminated infection

3.

Disseminated histoplasmosis*

Bacterial Infection
1

Disseminated (not just pulmonary or lymphatic) M. avium-intracellulare or

M. kansasii
2.

E.

Extrapulmonary tuberculosis*

Noncongenital Viral Infection

>

month) mucocutaneous herpes simplex

1

Chronic

2.

Histologically evident cytomegalovirus infection, including liver or

(

1

node
3.

h

Not

Progressive multifocal leukencephalopathy

listed in original

CDC definition of AIDS but subsequently added.
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severe

in particularly virulent

lymph

,

.
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Table 3

Opportunistic Malignancies Indicative of a Defect in
Cellular Immune Function Associated with AIDS

Neoplasm
1

Kaposi's sarcoma

2.

High-grade, B-cell non-Hodgkin's
A. Burkitt's

person less than sixty years old)

lymphoma*

Undifferentiated non-Hodgkin's

B.

*Not

a

lymphoma

Primary brain

3.

(in

lymphoma, immunoblastic sarcoma

lymphoma

listed in original

CDC definition of AIDS

but subsequently added.

opportunistic infections or neoplasms can be diagnosed, and most of them can be treated.

However, the recurrent succession of these debilitating diseases

is

analogous to the Hydra

monster of Greek mythology, which grew back two heads for every one
is this

that

was cut

off. It

succession of diseases that causes the ultimate mortality from AIDS.

The problem

for the patient, the clinician,

the diminishing returns of each

new

and society

the cause of new complaints. Although individuals

Pneumocystis carinii pneumonia are

much less

question for each individual of whether
or

to

determine when

who have had their third episode of
who have had

likely to survive than those

their first, this kind of information only gives probablistic odds,

man dignity

how

at large is

intervention mandate a less thorough investigation of

life

and does not address the

extension at specific junctures promotes hu-

human suffering.
HIV may result in neurological disease after initial

Infection with

seroconversion but

more often manifests itself later in the course of HIV infection, though specific neurologi25
cal sequelae may be seen at any point in time. The most dramatic findings include dementia, encephalopathy, and neuropathies, which may involve either muscles or
sensation, or both, as well as involvement of the spinal cord.
infection
status

may be more anxious or depressed,

26

27

Individuals with

HIV

or both, because of the knowledge of their

and because of the social stresses attendant upon being a member of a high-risk

group and carrying a life-threatening virus, but independent of these other behavioral
modifiers,

HIV infection may alter psychological and neurological functions early in the

course of the

illness.

Thus, health care planners must integrate the psychosocial and

neuro-behavioral needs of individuals with

HIV infection in the calculations of the soci-

much as $8 billion to
$16 billion to the cost of health care in the United States by 1991 28
Immature immune systems appear to be even more susceptible to the ravages of HIV

etal costs

of infection, which have thus far been estimated to add as

infection,

presumably because there are no immunologic reserves

that

have developed

29
over several decades of successfully fending of f environmental challenges. Although a

consensus

among

experts does not exist regarding the frequency with which offspring of

HIV-infected mothers will be infected themselves, there
substantial figure, possibly the majority of live births.

30

is

general agreement that

it is

These children may be born

a

to

who are addicted to drugs or are from disadvantaged socioeconomic environwho have to cope with their own HIV infections with all those associated medical problems. Children born with HIV infection may encounter difficulties in

mothers

ments, or both, and

placement

if their

mothers and families are unable to care for them. Thus, the problem of

44

AIDS, which has grown rapidly

pediatric
larly
cal,

New York,

and

northern

New Jersey,

development of public

ethical concerns for the

Clinical

Management Issues:

The

major

first

major metropolitan areas — particu— raises additional medical, sociologi-

in several

and Miami

policy.

Diagnostic Concerns

clinical use of the

HIV antibody test was

for the

donated blood in order to protect the blood supply. 31 In the
utilization, a

first

purpose of screening

few years of the

test's

wide-ranging public debate occurred in which some individuals were propo-

nents of using the test to screen the entire population, or subgroups of the population,

such as individuals seeking marriage licenses; health care professionals; and individuals

more

entering hospitals or being prepared for major surgery. Opponents of these
indications for use of the
sively

more

improved and despite the

ability to utilize

independent corroboration with other

sophisticated tests such as the Western blot, testing for antibodies

produce an unacceptably high number of false positives, particularly

in

still

32, 33

Another concern voiced by opponents of large-scale

seemed to

low prevalence

areas, even though the use of a corroborative test substantially reduces the
false positives.

liberal

HIV antibody test pointed out that despite the test being progres-

number of

testing of the

general population was that even

if all individuals identified as seropositive were truly
were identified as seropositive there would be no effective
therapies available to offer them. They would have knowledge that they were at increased
risk for AIDS and would be at risk for many types of discrimination if the information

infected with HIV, once they

could not be absolutely protected, with no prospect for reversing their infection.

How-

AZT is efficacious in prolonging life

ever, over the past year, clinical studies indicate that

AIDS and AIDS-related symptoms, 34 raising new questions of when to
At the present time, AZT has not been shown to be effective in preventing AIDS in

in individuals with
test.

asymptomatic HIV-seropositive individuals, but the studies that are currently under way
to evaluate this possibility could radically alter the clinical indications for

screening. If AZT or any other antiretroviral drug

promise

in

asymptomatic seropositives,

ing would be useful so that

HIV antibody

shown to prevent immunocomthe argument could run that proactive HIV testis

more individuals could be diagnosed and treated before the

onset of irreversible clinical disease.

The argument that the detection of early
into the general population

infection

may help prevent subsequent spread

and may reduce morbidity has been the basis for much of

current public health policy with regard to other sexually transmitted diseases. Since at
the present time

AZT looks promising but has not yet been shown to be effective for treat-

is much turmoil regarding this issue. Up to one-third of
AIDS or ARC who take AZT for more than several months have needed
repeated transfusions, and there are those who feel that AZT is a highly toxic drug. Since
the data suggest that individuals with lesser degrees of immunocompromise may tolerate

ing asymptomatic persons, there

persons with

the drug better,

whether

some rationale exists

for earlier treatment.

However, one does not know

HIV could become resistant to AZT over long periods of time,

only suppresses the virus's ability to replicate, and does not

from the body; other chronic viruses

(for

kill

since the drug

the virus or

remove

it

example, herpes simplex) can develop resistance

to suppressive therapeutic agents.

Other

clinical indications for the

status are

knowledge of an individual's

HIV and immunologic

emerging. For example, in children, the use of live virus vaccines, even though

the organisms utilized in the vaccines are avirulent, could result in an HIV-infected im-

45

New England Journal of Public Policy

munocompromised child becoming very ill with a disseminated viral infection that the
vaccine was designed to avoid. Family members may be in high-risk groups themselves
and could be susceptible

to serious infections

who had been recently

matic children

from viruses

that

were excreted by asympto-

vaccinated. Thus, the public

is left

with a fairly

which no proven interventions have been shown to alter the natural
infection in asymptomatic individuals, though several interventions are on

volatile situation, in

history of HIV

the horizon. Individuals
if

who

are infected with

they are going to be exposed to

new

HIV may benefit from knowing about this

infectious agents; however,

in noting that these are theoretical concerns, not

one must be cautionary

ones that are currently standard medical

— and one can only hope that
—
then HIV diagnostics will be increasingly more useful.
they proceed at a rapid pace
practice.

It is

clear that as the medical advances continue

The test itself will have more meaning

for individuals

when clinicians have something

to

offer them. In the meantime, the public debate about these issues should help to educate

both policymakers and clinicians as to the need to be very clear in their
they want individuals

to be screened for

own minds why

HIV

HIV screening's use as a tool for the modification of high-risk behaviors, and thereby
as a tool to decrease the spread of the retrovirus,

makers have

felt

the screening should be

is

one of the major reasons

more widely

that policy-

available. In a context of a

program

HIV testing may be helpful for specific indiYet it is difficult to generalize about the efficacy of HIV testing itself, since very

of intensive education about risk behaviors,
viduals.

few individuals undergo antibody testing without receiving some form of counseling,

which may be more relevant

The

to potential behavior changes.

substantial changes in high-risk behaviors

by the gay and bisexual men

in

one

Boston study were similar whether individuals were antibody -positive or -negative and
whether or not they knew their

test results.

On the basis of studies in which individuals

35

enter as volunteers, are given guarantees of confidentiality, and are not under scrutiny by

public health officials,
that people

know

their

it is

particularly hard to generalize about the effect of mandating

HIV antibody test results. One can only wonder whether manda-

tory testing could serve merely to intensify the development of an underground that could

be more refractory to the educational messages available
testing sites,
ticipate.

and other

in studies,

community-based

institutions that offer the test without coercing individuals to par-

The maintenance of a dialogue between the patients and their providers can allow
when it is appropriate to perform HIV testing and

for mutually reinforcing decisions as to

what kinds of support the patient will subsequently need

in order to maintain safer sexual

practices and to receive appropriate medical follow-up.

Therapeutic Concerns
Another major dilemma for clinicians taking care of individuals with
infection relates to the pace of clinical trials.

infection are not receiving medication to counteract the progressive

associated with HIV.

Most newly

AIDS and HIV
HIV

At the present time, most persons with

available drugs for treating

in the

ATEUs and Clinical Studies Groups

trally

coordinated to perform multicenter clinical

immunocompromise

HIV infection will be tested

(CSGs), which are federally funded and centrials.

A consortium of Harvard Medi-

Beth Israel, New England
New England. The ATEUs have begun sev-

cal School-affiliated hospitals (Massachusetts General,

Deaconess)

is

the only such treatment site in

eral protocols utilizing

AZT and are planning more studies to look at newer antiretroviral

drugs. Since the criteria for inclusion in a specific clinical study must be fairly rigid, and
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many

since

individuals

may

fall

between the cracks

in

terms of the progression of their

specific problems, a large

underground has already developed

from Mexico and overseas

in order to give individuals with

to

procure medications

AIDS and symptomatic HIV

make their own decisions about whether they would want to
Of great concern to clinicians is the fact that treatment with the

infection the opportunity to

receive a specific drug.
first

two highly publicized agents (Suramin and HPA-23) which act against the HlV-spe-

cific

enzyme, reverse transcriptase, turned out

infections

uals

would have been. Thus,

in the

may become more impressed by

to

HIV

be more toxic than the untreated

absence of meticulous basic research, individ-

the merchandising of purported panaceas

thereby expose themselves to potential harm.

By the same rationale,

early

and

HIV testing

may be useful because an individual may be at a better point to take action that can prevent
a more rapid decline in immunologic function. Many clinicians are concerned that drugs
may not be tested soon enough on less symptomatic, seropositive persons. Many asymptomatic individuals, perceiving themselves to be at increased risk for developing sympto-

matic

HIV infection in the near future,

are clamoring to receive

studied agents, and they indicate that they do not want to

sit

AZT or other, less

and wait while

their

immuno-

logic function inexorably declines. If many of these minimally symptomatic individuals

had taken HPA-23 or Suramin, they would have caused themselves more harm than benefit.

Thus, the federal health authorities feel that in studying new and promising agents,

they must balance the progressively increasing gravity of the epidemic against the need to

conduct studies in a careful and organized fashion.

Many hopes have been raised regarding drugs besides AZT,
gen, Phosphonoformate, and a host of other compounds. 36

now undergoing initial clinical trials,
investigators

37
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such as Ribavirin, Ampli-

Many of these drugs are

but the process can be a long and arduous one. First,

must develop a hypothesis as

to

why a specific

agent

may work in a test tube

and must demonstrate the efficacy of the compound against HIV-infected
studies in

humans have to

its toxicities.

Then, studies have to show that in human beings a specific drug may have

efficacy against
test

HIV infection. The traditional investigational gold standard has been to

a candidate drug in

humans

against a placebo in a randomized, controlled fashion,

utilizing subjects that are selected to
teristics.

cells. Initial

evaluate the pharmacokinetic properties of the drug as well as

be similar

in

terms of infection and disease charac-

Many of the promising reports about agents other than AZT do not involve ran-

domized, controlled

trials

and thus are often a series of anecdotes. The

erratic nature of

HIV infection makes noncontrolled trials difficult to interpret, since some individuals
may remain asymptomatic for as long as nine years after HIV infection, while others may
develop AIDS within a year after seroconversion. Individuals with Kaposi's sarcoma, in
particular, constitute a subgroup that in the absence of opportunistic infections may remain quite well, with fairly intact immunologic function, for long periods of time.
The clinical end points that are used to evaluate the efficacy of particular therapies are
still not standardized. If death is utilized as an end point, one has to follow a large cohort
of individuals with fairly advanced

HIV infection in order to establish an adequate differ-

ence between a new therapy and a placebo. This was done in the case of the
but the data in that study indicated that individuals

trial

of AZT,

who had ARC tended to benefit more

from AZT than those with AIDS. This would suggest that AZT would be better utilized
individuals who might have earlier stages of HIV infection. However, the AZT trial in
asymptomatic HIV-seropositive individuals may have to go on for at least three years
before

it

can be established whether treatment with

ive effect to warrant the toxicities that

AZT has a sufficiently large protect-

may be encountered in the course of therapy.
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does not use death as an end point, but rather opportunistic infections, the cohort size

must

be large and homogeneous

still

at the outset in

order to produce meaningful data that

can establish the efficacy of a specific agent. The clinical and laboratory

criteria,

which

are needed to include individuals in specific cohorts and to assess the effectiveness of
specific agents, have not yet
feel that the

been routinely standardized. For example, some individuals

presence of thrush

more concerned by

39
a particularly bad prognostic sign, whereas others are

is

the persistence of constitutional

symptoms.

can compare an asymptomatic person with thrush to a person

who has persistent fevers,

weight and

chills,

It is

not clear whether one

who has

lost significant

and sweats and multiple hematologic abnor-

most useful immunologic criterion for inclusion in a specific
would be evaluated in a drug trial would be the absolute T-helper lymphocyte
This has been shown to be useful in epidemiological studies, but whether im-

malities. In the lab, the

group

that

number. 40

provement or
efficacy

parameter

stabilization in this

is still

is

the best predictor of chemotherapeutic

an open question. Several virologic parameters

useful as well, but further study

is

may be

epidemiologically

required as to their usefulness as prognostic markers

undergo antiretroviral chemotherapy. Patients who have positive cultures
HIV or who have been shown to have HIV antigen in their serum (patients may be

after individuals

for

antigenemic and not viremic) tend to be more likely to become clinically
periods of time. 41
after

42

However, the reversal of antigenemia or the

ill

over short

inability to culture virus

an individual has been treated with a drug may not ipso facto mean that the drug

is

highly effective. These parameters are undergoing careful study and will increasingly

become useful

in characterizing stages of

responses to infection with the retrovirus

ogy

that

would allow

gate markers as a

HIV infection,
mean

that

but the highly individualized

it is still

very hard to establish a typol-

clinicians to give short trials of therapeutic agents

means

be no quick answers as

for proving

to

and

utilize surro-

drug efficacy. In summary, in the short run there will

which drugs are the most

ongoing studies of
which prove to be

effective; rather,

natural history will be necessary, unless novel agents are developed

highly effective in altering or reversing the HIV-induced immunodeficiency and

se-

its

quelae.

The need

for long-term, prospective, careful studies of individuals, utilizing placebos

and careful controls,

is

clear-cut. Yet, given the

HIV infection, many clinicians

dered by

Some individuals have

felt that historical

magnitude of human suffering engen-

feel that

an academic approach

is

unacceptable.

controls can be used to establish baseline rates of

progression in the natural history of HIV infection and that these can be compared to
individuals

controls

is

who are treated with

that as the

specific regimens.

The problem with using

historical

epidemic evolves, there are changes in the natural history of HIV

which have been unanticipated. Thus, comparisons of people who were infected
HIV several years ago with those who are undergoing therapeutic regimens now may

infection

with

lead to skewed interpretations. For example, at the outset of the epidemic, almost onethird of individuals

who were initially diagnosed using the CDC

Kaposi's sarcoma, whereas
this diagnosis. It is

flects

changes

new

had

cases carry
re-

changes in certain biological cofactors (such as the use of

"poppers"), or decreased transmission of another viral cofactor.

The vagaries of the
clinical trials,

definition of AIDS

present time less than one-fifth of the

unknown whether the decreased incidence of Kaposi's sarcoma

in behavior,

volatile nitrites, or

at the

natural history of HIV have complicated the need for expeditious

and appropriate

clinical

concerns have been perceived by some segments of

the population as an insensitivity. This has led to the burgeoning of the therapeutic under-

ground and

to

an increased alienation from clinical investigators among some HlV-in-
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fected persons. Occasionally, individuals

gone so

who have participated

in

randomized

far as to utilize drug-analysis laboratories in order to assess

trials

have

whether they are

receiving a placebo, and have either dropped out of trials or have supplemented their regi-

mens with nonprotocol drugs because of their sense of urgency regarding
These anecdotes

treatment.

reflect the exceptions rather than the rule, but they underscore the highly

charged environment that

is

evolving in this time of uncertainty. Individual self-medica-

who

tion has the potential to create serious therapeutic problems, since if every individual

were HIV-infected were
be obtained

to

experiment with different types of drugs, the results that might

in specific clinical trials

would be

difficult to interpret.

But many seropositive

persons are uncomfortable not knowing whether they have received a placebo. The
creased availability of AZT and the lack of a standard, accepted criterion by
in prescribing the

drug create the potential to exacerbate

present time,

known only

it is

that individuals

in-

all clinicians

this situation further.

At the

who have had one episode of Pneumo-

pneumonia or who have constitutional symptoms and other ARC-like manihad their lives extended by taking AZT. However, many HIV-infected
individuals who have either minor opportunistic infections, such as thrush or zoster, or
cystis carinii

festations have

asymptomatic depressions
take

AZT.

in their T-helper

lymphocyte count, or both, are electing

the clinical trials of sicker individuals, they prefer risking the potential toxicities of
to waiting until
ful.

it is

clearly

shown

that taking the

drug

at earlier stages

of infection

Blanket statements saying that individuals must either be in clinical

medication are not

realistic in the current climate.

On the other hand,

if

trials

to

from

In the absence of clear-cut data and through the process of extrapolating

AZT

is

use-

or not take

everybody did

exactly as they pleased, utilizing any available drugs through the black market, further

knowledge about the efficacy of antriretroviral therapy could be
limited.

clinical providers,

critically

delayed or

An ongoing dialogue among researchers,
and the communities at risk for HIV infection must continue, in order

There are no easy or

glib answers.

to address these highly urgent

human needs

in a responsible fashion. Yet

an adequate

level

of scientific rigor must also be maintained so that these crucial questions can be answered
as rapidly as possible.

Up until now,

clinical trials

have tended to look for the magic bullet, that

is,

a single

drug that will attenuate the effects of HIV infection. However, many researchers
this

approach may be simplistic, since the individual with

problems. Because the virus

is

immunosuppressive, the individual must have his or her

immune system restored if the onset of opportunistic
avoided. At the

same

first

infections or malignancy is to

time, the retrovirus itself must be inhibited

to prevent the extension of the infection

Some of the

drugs to treat

feel that

HIV infection faces two types of

from

be

replicating in order

and subsequent further immunosuppression. 43

HIV infection were stimulators of the immune

44

system,

such as interferon and interleukin-2. 45 Whereas they tended to increase the numbers of

lymphocytes which could potentially fight infection, they also tended to enhance the
ity

abil-

of HIV to replicate, thus abetting infection, and were ultimately not successful by

themselves. Drugs like

AZT inhibit specific enzymes of the virus and prevent it from

immune system by themselves. Thus, the possibility
combined chemotherapy with an immunostimulatory drug and a drug that acts
specifically against the virus could be a major answer in treating individuals with HIV
infection and preventing further immunologic compromise. 46 However, in order to assess
adequately the potential toxicities of individual agents, such trials would have to be performed serially; in other words, the effects of either drug by itself would first have to be
assessed, and only then could the drugs be studied in combination. Thus, some ap-

multiplying, but do not restore the
exists that
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proaches offer

much promise,

but even

more time may be required

to study

responsible fashion, thus further straining the patience of individuals

immunologic compromise. Some
scientifically

who

feel that although serial trials of these

them

in a

are at risk for

drugs represent a

worthwhile approach, so many individuals could clinically deteriorate be-

fore definite data

were collected

that

combination studies should begin in a more expedi-

tious fashion. Previous medical experience shows, however, that

when two drugs

are

given together, unexpected synergistic toxicities supervene instead of synergistic therapeutic effects. Dual therapy

may

alone (antagonism) in vivo even

result in lessened therapeutic efficacy of either

if in vitro

drug

data look promising. Thus, the dialogue be-

tween the affected individuals and the research community must take each side

into ac-

The old dictum, Primum non noce (First do no harm), must be balanced against
the problem that can result from too much delay in initiating a promising therapeutic
regimen. The only answer is constant questioning and dialogue in order to expedite the
process of making useful combination treatments available, without rushing to judgment
in such a way that more individuals are harmed because of inadequate antecedent study.
count.

Care-Related Issues

The AIDS epidemic

many

raises

viduals infected with

HIV who

issues regarding the optimal delivery of services to indi-

subsequently develop problems related to

promise. Although persons with

AIDS have a markedly

shortened

life

can respond well to specific treatment regimens, particularly after their
opportunistic infection.

The

initial

first

episodes of

approach toward the management of patients with

infection tended to be technologically intensive,

and led

HIV

to patients being hospitalized for

longer periods of time. The model developed in San Francisco
lizes outpatient

immunocom-

expectancy, they

is

one

that optimally uti-

home care and treatment in the ambulatory
the ways in which health care is financed in many areas tend to

resources and maximizes

setting. Unfortunately,

create disincentives for early discharge and the provision of comprehensive outpatient
services. This will

become

increasingly penny-wise and pound-foolish, given the avail-

regimens that require some

ability of prophylactic

level of medical expertise,

such as the

administration of aerosolized Pentamidine in order to prevent the recurrence of Pneumocystis carinii

pneumonia. Health care planners and policymakers will need

talk to clinicians, patients,

tion in order to create the

munity

settings,

and advocacy groups for individuals

most

at

to continually

high risk for

HIV infec-

satisfactory approaches to caring for individuals in

which may provide a

less depressing

com-

environment and which certainly

provide a less costly one. In order for these novel programs to be successful, there must

be a comprehensive
including

set of supports

home health

specialists, nutritionists,

patients

do not return

which includes a wide range of health care providers,
and occupational rehabilitation

aides, nursing assistants, physical

and mental-health-care workers, so

to tertiary institutions with

that the deinstitutionalized

more complicated medical problems

could have been anticipated had the appropriate interventions been instituted

that

earlier.

Health care providers such as physicians and nurses need to increasingly become aware
that

many

of the individuals at highest risk for

tional" social environments.

hanced

if

The

HIV

infection

do not come from "tradi-

effectiveness of the health care

team can only be en-

providers recognize the validity of same-sex spouses, nonnuclear family units,

and nonmedical resources
norities. Since so

much

in

communities

that

comprise sexual, cultural, and racial mi-

of HIV infection relates to behavioral issues, providers must
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educate themselves about alternative lifestyles and must understand

how

critical

it is

that

they relate to clients as nonjudgmental care givers and educators.

HIV
many

infection results in

problems

that involve the

whole

patient,

who is the sum total of
who are

parts greater than individual subspeciality concerns. Therefore, patients

infected with the retrovirus need to be approached clinically by a multidisciplinary

team

of health care providers. This team must include subspecialists in areas of expertise such
as infectious diseases, hematology, oncology,

pulmonary diseases, gastroenterology, and

often a host of other subspecialities. However, these patients have a great need to have
their care integrated; thus, there will

be a continuing need for primary care generalists to

serve as their gateway to the health care system. In

some university

hospital settings,

infectious disease specialists tend to be the primary providers of care for individuals with

symptomatic HIV infection, but in others, general internists and family practitioners have
done a fine job and have tended to be the health care providers who oversee the series of
consultations that may be necessary in the course of HIV infection for any given individual.

The health care team can be

tion,

greatly enhanced by the inclusion of nurse practitioners

who have developed specific skills around AIDS and HIV infecsince individuals with these problems may need a great deal of education, moral

and physicians'

assistants

support, and clinical monitoring that do not necessitate the constant involvement of the
subspecialist. In addition, the

from neurologists

to social

ongoing involvement of mental health professionals ranging

workers can greatly enhance the

HIV infection to function well in

society.

Not every

ability of individuals

individual with

invariably need to see the psychiatrist or the gastroenterologist, but

HIV
it is

with

infection will

important to de-

velop a referral network that will allow for a rational pattern of integrated health care for

each individual

who is diagnosed with HIV

infection

and

its

attendant clinical sequelae.

Infection Control

The last major policy issue regarding HIV infection relates to infection control. As with
so many other aspects of the AIDS epidemic, the public dialogue on this issue has tended
to careen

between hysteria and apathy, whereas the most appropriate course

is

one of

prudent caution based on the well-documented epidemiology of retroviral infection. The
precautions that providers need to take regarding

HIV infection are virtually identical to

those which are taken with respect to any bloodborne disease and have been recently well

described by the Centers for Disease Control. 47

One must add the caveat that individuals
who are infected with HIV may be more susceptible to certain types of infections — for
example, tuberculosis — that may in and of themselves be contagious to individuals with
intact immune systems. Therefore, clinicians need to respond with the appropriate
thoughtful caution in the care of individuals with HIV infection. Thus, if an individual
who has HIV infection has an atypical chest x-ray and is coughing, it behooves the provider to suggest that the patient be placed on respiratory isolation until the diagnosis of
tuberculosis

is

excluded. However, irrational infection control procedures serve only to

stigmatize the individual, give a false sense of security to staff members, and lead to sub-

optimal, alienated medical care.
Traditional practice has included the documentation in the medical record of all information that could possibly be of clinical importance, on the presumption that no clinician's

memory

future.

is infallible and that others may benefit from this documentation in the
However, antidiscrimination provisions against individuals with HIV infection

57
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are lacking in most jurisdictions, and since, particularly in small medical settings,

it is

may be at risk from exdocumented. Therefore, many have felt that

very difficult to keep medical information inviolate, individuals
ternal social sanction if their

HIV status is
HIV infection should never be placed in the medical rec-

information about persons with
cord. However,

where HIV-related information has been obtained

ion and where knowledge of this information on the part of other

care team
not on the

in a

noncoercive fash-

members of the health

may be important for patient management, it seems that discussion should focus
compromise of medical care, but on how best to protect individuals from capri-

cious or inappropriate disclosure and subsequent discrimination. Therapeutic interventions available for HIV-infected individuals,

it is

hoped, will continue to increase over the

next few years, and as they do, the likelihood will also grow that within the health care

system more individuals will be disclosed as HIV-infected. In order to avoid further exacerbation of the patients' need for comprehensive medical care, which

documentation of their
tients is urgently

may necessitate

clinical status, legislation that addresses the just

needed. Discussions

among medical providers,

those

concerns of pa-

who make public

and the general public must lead to a resolution that creates an environment
which individuals will not be stigmatized in the process of seeking health care.

policy,

With more than one million HIV-infected persons
potentiate alienation

in the

United States, any actions that

from the health care system and impede education around

tion are inappropriate. In the midst of this distressing epidemic, all of us

providers, patients, and the public
late

new

in

risk reduc-

— researchers,

— face the great challenge of having to rapidly assimi-

technical information while remodeling the anachronistic social systems that tend

to increase the underlying anxieties. Until

we have definitive therapeutics and chemopro-

phylaxis, these anxieties will persist. *§*
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Glossary continued from page 36

Immunocompromise.

Alterations in

immune

function which are suggestive of a

decreased ability to fight off infections and the development
of malignancies.

Immunoregulation

Immunostimulation

The processes by which
munocompromise.

body

The process by which substances
the

In vitro.

the

immune

is

able to prevent im-

turn

on

specific parts of

system.

Experiments that occur

in artificial laboratory environ-

ments outside the living body.
In vivo.

Experiments

that

occur in the living organism, either using

animal models or clinical studies that take place in humans.

Maculopapular.

A rash that is reddened, with some irregular raised surfaces.

Neurological syndrome.

Any process that results

in

an alteration of the nervous

system. This can result in confusion, coma, muscle weakness, strange sensations, or any combination of these.

Neuropathy.

Any

Opportunistic infections/

Infectious diseases or tumors that develop because of a

neoplasms.

weakening of the immune system, so

process that impairs the functioning of specific nerves.

that processes

which

are usually quite innocuous take advantage of the resultant

immunocompromised

state.

Persistent generalized lym-

Swollen glands in more than one noncontiguous

phadenopathy (PGL).

out the body which stay enlarged for at least three months.

Synergism.

Any combination that results

site

through-

in a multiplicative effect

rather than an additive effect.

T-helper lymphocyte.

A type of white blood cell that is responsible for orchestratmany of the interactions of different, other blood cells
immune system. This is one of the cell types that
become particularly affected by HIV, and the T-helper
ing

in the

lymphocyte count can be a useful marker

in following the

progress of HIV infection in specific individuals.

Thrush.
Zoster.

A yeast infection of the tongue.
Reactivation of the chicken pox virus, also
gles.

known as

shin-

This usually results in a painful band either on the

trunk or on the face, with painful blisters.
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"I don

't

consider myself a person

who dying from AIDS.

certainly consider myself a person

I don
in the

't

consider myself an

's

who s been

living with

I

AIDS.

AIDS victim, and I really wish people

media would stop using that terminology. I think that's one

of the most damning things that you can say about a person,
that they 're just a victim,

come

and I think that part of the way I've

to look at this is that

I'm a person who 's

still in

control of

my life and I refuse to be victimized by AIDS or anyone who
connected with

is

this disease in

any way. I maintain
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control.
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Candida esophagitis.

Yeastlike fungus infection of the esophagus.

Hepatitis B.

Viral infection

whereby a small virus attacks the

liver,

often

producing jaundice.

Hyperallergenic subjects.

People

who have heightened allergic

responses.

lymph nodes,

Persistent generalized

Persistent inflammation of the

lymphadenopathy (PGL).

the axilla and groin, in response to an infection.

particularly

Transplacental or

Transmission of the virus from the bloodstream of the

placental spread.

mother to the blood of the unborn baby.

58

